Ledipasvir-d16

O=C(OC)NC(C(N([C@@H](C1=NC=C(C2=CC(C(F)(F)C3=C4C=CC(C5=CC=C6N=C([C@@H]7N(C(C(NC(OC)=O)([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)[C@@]8([H])CC[C@]7([H])C8)NC6=C5)=C3)=C4C=C2)N1)C9)CC%109CC%10)=O)([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H]

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Link JO, et al. Discovery of ledipasvir (GS-5885) : a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57 (5) :2033-46|[3]Hernandez D, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013 May;57 (1) :13-8.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.